GlassScriptPhysician profile
Ruchika Talwar
NPI 1003349440
$8,291.95
in general payments reported to CMS, 2019-2025
18 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $407 · 2021: $737 · 2022: $1,144 · 2023: $950 · 2024: $3,168 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,200 · Food and Beverage: $2,062 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,200.00 |
| Food and Beverage | $2,061.65 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $3,004.89 | 2022-2025 | Jelmyto |
| Medtronic, INC. | $942.57 | 2021-2022 | |
| Immunitybio, INC. | $800.00 | 2025 | |
| Medtronic USA, INC. | $704.30 | 2019-2020 | |
| Photocure INC | $665.04 | 2022-2024 | Cysview |
| Boston Scientific Corporation | $434.98 | 2019-2024 | Advantage System, Lithovue |
| Bayer Healthcare Pharmaceuticals INC. | $376.02 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $294.51 | 2023-2024 | Erleada |
| Baxter Healthcare | $133.78 | 2019-2020 | |
| Genzyme Corporation | $121.30 | 2022 | |
| Astellas Pharma US INC | $120.91 | 2019-2021 | |
| Johnson & Johnson Health Care Systems INC. | $109.02 | 2023 | Erleada |
| Ferring Pharmaceuticals INC. | $106.71 | 2025 | Adstiladrin |
| Janssen Biotech, INC. | $105.91 | 2024 | Akeega, Erleada |
| Pfizer INC. | $96.79 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baudax Bio INC. | $93.29 | 2021 | |
| Progenics Pharmaceuticals, INC. | $91.01 | 2025 | |
| Neotract INC. | $90.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchika Talwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.